Skip to main content
SCYX
NASDAQ Life Sciences

SCYNEXIS Board Approves 1-for-8 Reverse Stock Split, Effective May 29

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.68
Mkt Cap
$58.096M
52W Low
$0.565
52W High
$1.31
52W Position info
20% above low
Off High info
48% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

SCYX sits 20% above its 52-week low of $0.565.

Summary

SCYNEXIS announced its Board of Directors approved a 1-for-8 reverse stock split, effective May 29, 2026, to address Nasdaq listing requirements.


Key Events · Corporate Governance and Compliance · SCYX

  • Board Approves 1-for-8 Reverse Split

    The Board of Directors finalized the reverse stock split ratio at 1-for-8, following shareholder approval of a range.

  • Effective Date Set

    The reverse stock split will be effective on May 29, 2026, with split-adjusted trading beginning June 1, 2026.

  • Authorized Shares Reduced

    The total number of authorized common shares will decrease proportionally from 150,000,000 to 18,750,000.

  • Nasdaq Compliance Action

    This action is intended to help the company regain compliance with Nasdaq's minimum bid price requirement.


Analysis · SCYX · Life Sciences

The Board's approval of a 1-for-8 reverse stock split, following shareholder authorization, is a critical step for SCYNEXIS to regain compliance with Nasdaq's minimum bid price requirement. While necessary to maintain listing, reverse splits often reflect underlying challenges and can be perceived negatively by the market. The proportional reduction in authorized shares also aligns with the new share count.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SCYX was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $58.1M. The 52-week trading range was $0.57 to $1.31. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SCYX - Latest Insights

SCYX
Nov 05, 2026, 8:01 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.84
Real-time Price: $2.79 info
Change: -$1.05 (-27%) info
Market Cap: $28.964M info
SCYX
Oct 06, 2026, 7:53 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.18
Real-time Price: $2.79 info
Change: -$2.39 (-46%) info
Market Cap: $28.964M info
SCYX
Sep 28, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.71
Real-time Price: $2.79 info
Change: -$1.92 (-41%) info
Market Cap: $28.964M info
SCYX
Sep 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.46
Real-time Price: $2.79 info
Change: -$3.67 (-57%) info
Market Cap: $28.964M info
SCYX
Aug 10, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.27
Real-time Price: $2.79 info
Change: -$2.48 (-47%) info
Market Cap: $28.964M info